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Abstract
Introduction: This study aimed to determine whether, as in osteoarthritis, increased levels of interleukin-6 (IL-6) are
present in the synovial fluid of patients with symptomatic cartilage defects and whether this IL-6 affects cartilage
regeneration as well as the cartilage in the degenerated knee.
Methods: IL-6 concentrations were determined by ELISA in synovial fluid and in conditioned media of
chondrocytes regenerating cartilage. Chondrocytes were obtained from donors with symptomatic cartilage defects,
healthy and osteoarthritic donors. The effect of IL-6 on cartilage regeneration and on metabolism of the resident
cartilage in the knee was studied by both inhibition of endogenous IL-6 and addition of IL-6, in a regeneration
model and in osteoarthritic explants in the presence of synovial fluid, respectively. Readout parameters were DNA
and glycosaminoglycan (GAG) content and release. Differences between controls and IL-6 blocked or
supplemented samples were determined by univariate analysis of variance using a randomized block design.
Results: Synovial fluid of patients with symptomatic cartilage defects contained more IL-6 than synovial fluid of
healthy donors (P = 0.001) and did not differ from osteoarthritic donors. IL-6 production of osteoarthritic
chondrocytes during cartilage regeneration was higher than that of healthy and defect chondrocytes (P < 0.001).
Adding IL-6 increased GAG production by healthy chondrocytes and decreased GAG release by osteoarthritic
chondrocytes (P < 0.05). Inhibition of IL-6 present in osteoarthritic synovial fluid showed a trend towards decreased
GAG content of the explants (P = 0.06).
Conclusions: Our results support a modest anabolic role for IL-6 in cartilage matrix production. Targeting multiple
cytokines, including IL-6, may be effective in improving cartilage repair in symptomatic cartilage defects and
osteoarthritis.
Introduction
Cytokines are thought to play an important role in articu-
lar cartilage degeneration [1]. In rheumatoid arthritis (RA),
the pro-inflammatory cytokines tumor necrosis factor-a
(TNF-a) and interleukin-1 (IL-1) are known to have pivo-
tal roles in its pathophysiology [2]. In addition to IL-1 and
TNF-a, interleukin-6 (IL-6) has been demonstrated to
play a role in cartilage degeneration in RA. In mice models
of RA, cartilage destruction was shown to be dependent
on IL-6 [3,4]. Furthermore, tocilizumab, a humanized
monoclonal antibody against the IL-6 receptor, now has
an established role in the treatment of RA [5]. Besides effi-
cacy in the amelioration of clinical signs and symptoms,
tocilizumab has also been demonstrated to reduce joint
space narrowing and levels of cartilage degradation
biomarkers [6-8].
Although not as pronounced as in RA, mild and intermit-
tent inflammation is frequently observed in symptomatic
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focal cartilage lesions, a condition thought to predispose to
the development of osteoarthritis (OA), and in OA.
Elevated concentrations of inflammatory mediators, includ-
ing IL-6, have been found in the serum and synovial fluid
of OA patients [9-16] and correlated to radiographic knee
OA [17,18]. However, the presence of IL-6 in joints with
symptomatic cartilage defects has not been evaluated until
now. In other joint injuries known to predispose to OA,
such as anterior cruciate ligament (ACL) injuries [19-21]
and meniscal tears [12,22], increased levels of IL-6
have been detected in the synovial fluid. High levels of
intra-articular inflammatory cytokines may, in addition to
causing degeneration, also hamper tissue regeneration as
cartilage repair is affected by the composition of the syno-
vial fluid [23-25].
In OA most of the IL-6 present in the knee originates
from the synovium [26]. However, chondrocytes in culture
are capable of producing IL-6, albeit at low levels under
most conditions [27-29]. Various stimuli, such as inflam-
matory molecules [30,31] and binding of (fragmented)
matrix components, which bind through discoidin domain
receptor 2 (DDR2) [32,33], have been reported to induce
IL-6 synthesis, and these mechanisms are also proposed to
play a role in OA. Chondrocytes can be stimulated by IL-6
either by binding directly to the gp80 receptor or, more
commonly, through trans-signalling, in which IL-6 binds
first to the soluble IL-6 receptor a (IL-6Ra) in the synovial
fluid, and then forms a heterodimeric association with the
membrane-bound gp130 receptor [34].
Despite its possible role in OA, studies investigating the
role of IL-6 in OA models have provided inconsistent
results. In vitro stimulation of chondrocytes with IL-6 has
revealed anabolic effects, such as up-regulation of tissue
inhibitor of metalloproteinases-1 (TIMP-1) [35] and type
II collagen [36], as well as catabolic effects, such as down-
regulation of cartilage matrix genes [37,38], inhibition of
proteoglycan synthesis [39] and stimulation of aggrecanase
production [40,41]. In vivo models have also revealed both
chondroprotective and chondrodegenerative properties of
IL-6. A protective role of IL-6 in a spontaneous OA model
was reported in aging male mice [42], but through both
mechanically induced OA and OA induced by hypoxia-
inducible factor-2a (HIF-2a), IL-6 was identified as the
mediator of cartilage degradation [43]. However, many
other studies have failed to demonstrate a direct effect of
IL-6 on cartilage matrix metabolism [44-46]. One of the
explanations for this lack of effect may lie in the simplified
set-up of many studies in which IL-6 has been added,
since the action of IL-6 may depend on other factors in
the joint, in particular in the synovial fluid.
This study evaluated the presence of IL-6 in the synovial
fluid of patients with symptomatic cartilage lesions and
patients with late stage OA, its production by chondro-
cytes isolated from these patients, and its role in cartilage
regeneration. In addition, to evaluate the possible effects
of high levels of IL-6 in the synovial fluid on cartilage in
the knee, we cultured OA cartilage explants in the pre-
sence of OA synovial fluid in which IL-6 was selectively
inhibited.
Materials and methods
Synovial fluid and cartilage sample collection and cell
isolation
Collection of all patient material was done according to
the Medical Ethical regulations of the University Medical
Center Utrecht and according to the guideline ‘good use
of redundant tissue for clinical research’ constructed by
the Dutch Federation of Medical Research Societies on
collection of redundant tissue for research [47]. This study
does not meet the definition of human subjects’ research
or require informed consent and anonymous use of redun-
dant tissue for research purposes is part of the standard
treatment agreement with patients in our hospital [48].
Macroscopically healthy articular cartilage (n = 6) and
synovial fluid (n = 20, age 25 to 47, average 40 years) were
obtained from donors without any history of major joint
trauma, osteoarthritis or inflammatory joint disease and
absence of cartilage defects and synovial inflammation
upon inspection of the knee within 24 hours post-mortem.
Consistently, only one knee per donor was used. Defect
cartilage (n = 3) and synovial fluid (n = 22, age 20 to 48,
average 33 years) were obtained from donors undergoing
either microfracture or autologous chondrocyte implanta-
tion (ACI) for focal grade III and IV cartilage defects (only
grade III cartilage was used for chondrocyte isolation).
During those procedures, the cartilage defect was debrided
to remove all cartilage remnants down to the subchondral
bone and create a stable cartilage rim. The debrided carti-
lage was used for chondrocyte isolation. Chondrocytes
from this location were recently shown to have good
regenerative capacities compared to cells harvested from
non-weight bearing cartilage normally used for ACI [49].
Of the 22 patients with symptomatic cartilage defects, one
had an associated ACL injury and a history of partial
menisectomy, another three had previously received par-
tial menisectomies and one had undergone an ACL recon-
struction. OA cartilage (n = 12) and synovial fluid (n = 27,
age 53 to 81, average 70 years) were obtained from donors
undergoing total knee arthroplasty. Synovial fluid was
centrifuged at 13,000 g for two minutes to remove debris,
and stored at -80°C until use or analysis. Glucocorticoids
affecting cytokine production are not prescribed at
our institution for patients with focal cartilage lesions
and patients with end-stage OA eligible for total knee
replacement.
Cartilage samples were rinsed in phosphate buffered
saline (PBS), cut into small pieces and enzymatically
digested overnight at 37°C in a 0.15% collagenase type II
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(Worthington, Lakewood, NJ, USA) in Dulbecco’s modi-
fied Eagle’s medium (DMEM; Gibco, Life Technologies,
Bleiswijk, The Netherlands) with penicillin/streptomycin
(100 U/mL/100 μg/mL; Invitrogen, Life Technologies).
After digestion, the cell suspension was filtered through a
70 μm cell strainer (BD Biosciences, San Diego, CA,
USA), and the chondrocytes were spun down by 10 min-
utes centrifugation at 300 g.
Measurement of IL-6 levels
To determine the IL-6 levels in the synovial fluids of
healthy, defect and OA donors and in the conditioned
media of healthy, defect and OA chondrocytes during
regeneration, a multiplex ELISA was performed as pre-
viously described [50,51]. A total of 12 cytokines were
measured of which IL-6 was most differentially regulated
by healthy, defect and OA donors and hence chosen for
further investigation. Briefly, specific antibodies (i.a. rat
anti-human IL-6, MQ2-13A5; BD Biosciences) were
coupled to carboxylated beads (Luminex Corporation,
Austin, TX, USA). Recombinant human IL-6 (BD Bios-
ciences, #550071) was used to make a standard curve.
Synovial fluid samples were first treated with hyaluroni-
dase (type IV-S, Sigma-Aldrich, Zwijndrecht, The Nether-
lands) at a concentration of 20 U/ml for 30 minutes at
37°C and then filtered by centrifuging through a polypro-
pylene tube containing a 0.22 μm nylon membrane (Spin-
X column; Corning, Amsterdam, The Netherlands).
Subsequently, the synovial fluid samples were diluted 1:2
with HPE-0.1375% Tween (Sanquin, Amsterdam, The
Netherlands). To block possible interfering antibodies pre-
sent in the synovial fluid, the samples were diluted with an
equal volume of 10% (v/v) normal rat and mouse serum
(Rockland Immunochemicals Inc., Gilbertsville, PA, USA).
Medium samples were directly incubated with the coupled
beads. After incubation with the appropriate biotinylated
antibodies (i.a. biotinylated rat anti-human IL-6, MQ2-
39C3; BD Biosciences), samples were thoroughly washed
and incubated with streptavidin-phycoerythrin (BD Bios-
ciences) for 10 minutes. After washing, the samples were
measured and analyzed using the Bio-Plex suspension
system (Bio-Rad Laboratories, Hercules, CA, USA) with
Bio-Plex Manager software, version 3.0. The concentration
of IL-6 in the media and synovial fluid was expressed
as pg/mL using the standard curves. Results of specific
ELISAs for determination of IL-6 levels have previously
been shown to be comparable to multiplex ELISA for
conditioned medium, plasma and knee lavage samples
[22,26,50].
Regeneration culture
Isolated chondrocytes from healthy, defect and OA carti-
lage were expanded in a monolayer at 37°C and 5% CO2
at a seeding density of 5,000 cells per cm2 in expansion
medium consisting of DMEM, 10% fetal bovine serum
(Hyclone, Thermo Scientific, Etten-Leur, The Nether-
lands), penicillin/streptomycin (100 U/mL/100 μg/mL)
and 10 ng/mL basic fibroblast growth factor (bFGF; R&D
Systems, Minneapolis, MN, USA). After two passages
(P2), the chondrocytes were seeded on collagen type II-
coated (chicken sternal cartilage; Sigma-Aldrich, #C9301)
Millicell filters (Millipore Co., Bedford, MA, USA), at
1.6 × 106 cells per cm2. Chondrocytes were redifferen-
tiated for 28 days in redifferentiation medium consisting
of DMEM, 0.2 mM l-ascorbic acid-2-phosphate (AsAp;
Sigma-Aldrich), 2% human serum albumin (Sanquin
Blood Supply Foundation, Amsterdam, The Nether-
lands), penicillin/streptomycin (100 U/mL/100 μg/mL),
2% insuline-transferrine-selenium (ITS)-X (Invitrogen)
and 5 ng/mL transforming growth factor-b2 (TGF-b2;
R&D Systems). Since fibrillar type II collagen was pre-
viously shown to induce IL-6 release from chondrocytes
[32,33], we also measured the release of IL-6 from P2
chondrocytes (n = 3 healthy donors) seeded at a density
of 1.6 × 106 cells per cm2 on filters coated with type I col-
lagen (rat tail; BD Biosciences, #354249), and denatured
type I and II collagen. Collagen was denatured by heating
for 45 minutes at 70°C. Levels of IL-6 in the conditioned
media were determined by specific ELISA for IL-6 (Cyto-
set®; Invitrogen) according to the manufacturer’s
instructions.
Endogenous IL-6 production of defect chondrocytes
proved to be not significantly different from healthy
chondrocytes, which were both much lower than that of
OA chondrocytes. Therefore, the role of IL-6 endogen-
ously produced by defect chondrocytes (n = 3) and OA
chondrocytes (n = 3) was studied through blockage of IL-
6 with an activity-inhibiting antibody. To this end, the
medium was supplemented with either 1 or 4 ug/mL
anti-hIL-6 (purified mouse monoclonal IgG1; R&D Sys-
tems, #MAB206) or IgG1 isotype control (R&D Systems,
#MAB002). The dose of anti-hIL-6 was chosen based on
an IL-6-dependent murine plasmacytoma proliferation
assay, as described earlier [52]. Furthermore, IL-6 activity
was blocked with 100 ng/mL tocilizumab (RoActemra®,
Roche, Woerden, The Netherlands), a humanized mono-
clonal antibody directed against the IL-6 receptor. The
concentration of tocilizumab was chosen based on pre-
viously observed average concentrations of IL-6 receptor
in the synovial fluid of patients with OA of approximately
10 to 40 ng/mL [15,16]. Since the effects of IL-6 inhibi-
tion were limited in expanded cells, we also verified the
effects of IL-6 inhibition in freshly isolated OA cells (P0;
n = 3).
Endogenous IL-6 production was relatively low in
healthy chondrocytes, so the possible effects of high
concentrations of IL-6 were further investigated by the
addition of 10 ng/mL rhIL-6 with 25 ng/mL rhIL-6Ra
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(R&D Systems, #206-IL, #227-SR) to both healthy
(n = 3) and OA (n = 3) chondrocytes. Medium was
changed three times a week and supernatants were col-
lected and stored at -80°C until later analysis. Per condi-
tion, six filters were seeded with chondrocytes, five for
biochemical analyses and one for histological evaluation.
Osteoarthritic cartilage explant culture
OA cartilage from three donors was cut into explants of
approximately 1 mm by 1 mm with a mean wet weight (±
SD) of 7.8 ± 2.8 mg. Cartilage explants were cultured for
14 days in explant medium consisting of DMEM, penicil-
lin/streptomycin (100 U/mL/100 μg/mL), 1% ITS-X, 0.1
mM AsAp and 0.2% proline (Sigma-Aldrich), which was
supplemented with either 0 or 25% (v/v) pooled OA syno-
vial fluid from eight donors. Six explants per condition
were used, five for biochemical analyses and one for histo-
logical evaluation. To study the role of IL-6 present in the
synovial fluid, 4 ug/mL anti-hIL-6 or IgG1 isotype control
and/or 100 ng/mL tocilizumab were added to the medium.
Medium was changed three times per week and collected
and stored at -20°C until later analysis.
The role of IL-6 was also studied by the addition of IL-6
to the culture medium. Explants from eight OA donors
(11.3 ± 3.8 mg, minimum of three explants per condition)
were pre-cultured for 24 hours in culture medium after
which rhIL-6 (50 ng/mL) with IL-6 receptor (rhIL-6Ra;
200 ng/mL) [53] was added to experimental groups, but
not to control groups. Explants were cultured for an addi-
tional 10 days with medium renewal every other day and
the conditioned medium was collected and stored at -20°C
until later analysis.
Glycosaminoglycan and DNA analysis
After culture, the explants and the regenerated tissue were
digested overnight in a papain buffer (250 μg/mL papain
(Sigma-Aldrich) in 50 mM EDTA and 5 mM L-cysteine)
at 56°C, followed by quantification of the glycosaminogly-
cans (GAGs) content using the dimethylmethylene blue
(DMMB) assay [54]. The ratio of absorption at 540 nm to
595 nm was used to calculate the GAG content, using
chondroitin-6-sulphate (shark; Sigma-Aldrich) as a stan-
dard. The GAG content in conditioned medium was also
measured.
The DNA content in the papain digests was deter-
mined using a Picogreen DNA assay (Invitrogen) in
accordance with the manufacturer’s instructions.
Histological evaluation
Both regenerated tissue and explants were fixed in 10%
buffered formalin, dehydrated in alcohol, rinsed in xylene
and infiltrated and embedded with paraffin. For histology,
5 μm sections were stained with safranin-O (Merck,
Darmstadt, Germany) for GAG and counterstained with
Weigert’s haematoxylin (Klinipath, Duiven, The Nether-
lands) and 0.4% fast green (Merck) for nuclei and cyto-
plasm, respectively.
Statistical analysis
All statistical analyses were performed using SPSS 18.0
(SPSS Inc., Chicago, IL, USA). Results are displayed as
mean ± standard deviation (SD). Differences between con-
trols and IL-6 blocked samples and differences between
controls and IL-6 supplemented samples were determined
by univariate analysis of variance using a randomized
block design and post hoc LSD-test when four or more
conditions were compared to each other. Differences in
IL-6 concentration were determined by the Kruskal-Wallis
test, using post hoc Mann-Whitney U-test and Bonferroni
correction for synovial fluids, and using nested ANOVA
with post hoc t-test and Bonferroni correction for condi-
tioned media. Differences between the various collagen
coatings were determined by univariate analysis of var-
iance with post hoc t-test with Bonferroni correction.
Results
IL-6 in synovial fluid
The synovial fluid of donors with symptomatic cartilage
lesions contained significantly more IL-6 than that of
healthy donors (261 ± 385 pg/mL versus 64 ± 120 pg/mL,
P = 0.001), and was slightly lower but not significantly dif-
ferent from OA patients (396 ± 508 pg/mL, Figure 1). IL-6
levels in the five patients with symptomatic focal cartilage
defects and associated or previous ACL injury and/or par-
tial menisectomy were not significantly different from the
group as a whole (154 ± 70 pg/mL, P = 0.6).
IL6 production in cell culture
In regeneration cultures, chondrocytes of the various ori-
gins produced IL-6 reaching concentrations that were at
least 10-fold higher than the concentrations present in
the synovial fluid of the corresponding donor category
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Figure 1 Increased concentration of IL-6 in the synovial fluid of
patients with cartilage damage. Concentration of IL-6 in the
synovial fluid of healthy (H), symptomatic cartilage defect (CD) and
osteoarthritic (OA) donors. Note the logarithmic scale of the Y-axis;
a = P < 0.001, b = P = 0.001.
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(Figure 2). OA chondrocytes (9,368 ± 3,284 pg/mL) pro-
duced significantly more IL-6 than both healthy (2,814 ±
995 pg/mL) and defect chondrocytes (3,246 ± 2,089 pg/
mL, P < 0.001). There was no significant difference in IL-
6 production between healthy and defect chondrocytes.
To verify whether IL-6 production during regeneration
was induced by the fibrillar type II collagen used for coat-
ing the filters in this model, we measured IL-6 production
of regenerating chondrocytes on filters coated with various
collagens. There was no difference in IL-6 production
between type I and II collagen-coated filters and also
not between native or denatured collagen-coated filters
(Table 1). GAG and DNA content were also similar
between the various coatings.
Regeneration culture
To evaluate whether the high levels of IL-6 produced by
the chondrocytes during regeneration play a direct role
in cartilage regeneration, IL-6 was inhibited using an
activity-inhibiting antibody during regeneration of P2-
expanded defect- and OA chondrocytes. As no difference
was found in IL-6 production between healthy and defect
chondrocytes, only defect and osteoarthritic chondro-
cytes were studied. No effects were found on cartilage
matrix production, although an increase in DNA content
was found in OA chondrocytes (P = 0.009, Figure 3).
Verification of these results using non-expanded osteoar-
thritic chondrocytes similarly showed no effect on carti-
lage matrix production and also the effect on DNA was
no longer found (data not shown). Antagonism of the IL-
6 receptor with tocilizumab in osteoarthritic chondro-
cytes failed to influence GAG and DNA content (data
not shown).
In healthy and defect chondrocytes endogenous IL-6
production was much lower than in OA chondrocytes.
We, therefore, hypothesized that these cells could be more
responsive to stimulation with exogenous IL-6 than OA
chondrocytes. To examine whether exogenously added
IL-6 could affect regeneration, 10 ng/mL rhIL-6 with 25
ng/mL rhIL-6Ra was added during regeneration culture of
healthy and OA chondrocytes. In healthy chondrocytes,
exogenous IL-6 increased GAG production in the neocar-
tilage and a higher GAG/DNA ratio was found (P = 0.002,
Figure 4A, D). In OA chondrocytes, IL-6 decreased GAG
release (P < 0.001, Figure 4B) without affecting final GAG
content in the neocartilage. DNA content was not modi-
fied by the addition of IL-6 (Figure 4C).
Osteoarthritic explant culture
To study the effect of high levels of IL-6 present in the
synovial fluid on resident cartilage in the knee, we per-
formed OA cartilage explant studies in the presence of
OA synovial fluid in which IL-6 was inhibited. Ideally, we
would have also liked to perform these experiments using
synovial fluid and cartilage explants from patients with
chondral defects, but due to the very limited amount of
material that can be obtained from these patients this was
not feasible. In the absence of synovial fluid, inhibition of
IL-6 did not alter the GAG and DNA content of the carti-
lage explants, nor was GAG release affected (data not
shown). However, when IL-6 was inhibited in the presence
of synovial fluid a trend towards a decreased GAG content
of the explants was observed (P = 0.06, Figure 5A). In the
absence of IL-6 inhibitors, the addition of synovial fluid
increased the DNA content of explants (54.0 ± 28.0 μg/g
cartilage versus 33.6 ± 20.9 μg/gr cartilage, P = 0.002), and
this effect was abolished by blocking IL-6 (42 ± 20 versus
54 ± 28 μg/g cartilage). GAG release was neither affected
by the addition of synovial fluid nor by inhibition of IL-6
(Figure 5C).
Exogenous IL-6 in combination with soluble IL-6 recep-
tor in the absence of synovial fluid did not alter the GAG
(Figure 5B) or DNA content of the explants and also did
not modulate GAG release (Figure 5D).
Discussion
In this study, we show increased IL-6 levels in the syno-
vial fluid of patients with symptomatic cartilage defects
compared to normal subjects. The IL-6 levels in patients
with symptomatic cartilage defects were comparable to
levels in patients with OA. Furthermore, we demon-
strated for the first time that chondrocytes, especially
OA chondrocytes, produce high concentrations of IL-6
during regeneration. Inhibition of this endogenously
produced IL-6 did not affect cartilage matrix turnover,
but addition of extra IL-6 increased the GAG content of
neocartilage formed by healthy chondrocytes and
decreased GAG release by osteoarthritic chondrocytes in
an in vitro regeneration model. Furthermore, inhibition
of IL-6 present in the synovial fluid showed a trend
towards decreased matrix production in OA explants.
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Figure 2 Cartilage regeneration culture: IL-6 production.
Passage 2 expanded chondrocytes from healthy (H), defect (CD)
and osteoarthritic (OA) cartilage were seeded at high density on
type II collagen-coated filters and cultured during 28 days.
Concentrations of IL-6 in conditioned media of chondrocytes during
regeneration on Day 7 is shown; a = P < 0.001.
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Collectively, these results point towards an anabolic role
of IL-6 in cartilage repair, albeit with limited effects.
Inflammatory mediators secreted by synovium and pre-
sent in the synovial fluid have been demonstrated to affect
cartilage regeneration in vitro [23-26,55]. Therefore, it is
essential to characterize the mediators present in the syno-
vial fluid of symptomatic cartilage defects and osteoar-
thritic joints and to determine their role in cartilage
metabolism, in order to verify whether the outcomes of
cartilage repair procedures, such as ACI, could potentially
be enhanced by modulating the intra-articular environ-
ment. Levels of IL-6 comparable to those reported here
were previously shown in the synovial fluid from healthy
[10] and OA [10,12,56] joints; however, only limited data
were available on IL-6 levels in joints with symptomatic
focal cartilage defects. These are typically the joints that
Table 1 Effect of collagen coating on IL-6 and cartilage matrix production
Col I Col II Col ID Col IID P-value
IL-6 (pg/ml) 4,294 ± 2,152 4,604 ± 1,661 4,268 ± 1,446 5,463 ± 1,991 0.543
GAG (μg) 80 ± 24 85 ± 30 77 ± 25 85 ± 34 0.361
GAG release (μg/ml) 408 ± 29 410 ± 35 400 ± 38 498 ± 157 0.412
DNA (μg) 10 ± 1 9 ± 1 10 ± 2 10 ± 1 0.818
No significant differences were observed between type I collagen (Col I), type II collagen (Col II), denatured type I collagen (Col ID) and denatured type II
collagen (Col IID) coating on IL-6 production at Day 7, GAG content after 28 days of culture, cumulative GAG release during 28 days of culture and DNA content
after 28 days of culture. Results are displayed as mean ± SD.
Figure 3 Cartilage regeneration after inhibition of endogenously produced IL-6. Cartilage regeneration cultures of three defect (CD) and
three osteoarthritic (OA) donors with blockage of endogenous IL-6 with an activity-inhibiting antibody. (a-c) GAG content, GAG release and DNA
content after 28 days of culture in IL-6 blocked samples depicted as percent of control samples (mean ± SD); a = P = 0.009. (d) Safranin-O
staining of representative CD and OA chondrocyte donors regenerating either without (control; IgG isotype) or with inhibition (anti-IL-6) of
endogenous IL-6. Scale bars indicate 50 μm.
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will be treated to stimulate regeneration of cartilage with
techniques, such as ACI, and, therefore, of particular
importance for regenerative medicine strategies. Only one
study has reported on the levels of IL-6 in cartilage lesions
of variable depth, but did not specify whether the damage
was focal or whether more generalized OA-like cartilage
degeneration was present in the knee [56], which is an
important selection criterion for the indication of ACI.
However, IL-6 levels seemed to correlate with the grade of
cartilage damage as the synovial fluid concentration of
IL-6 increased with lesion severity. In our study, only
symptomatic focal grade III and IV cartilage lesions in
otherwise healthy knees were included. This is more clini-
cally relevant for cartilage regeneration, although no dis-
tinction was made between grade III and grade IV defects.
Most likely, IL-6 present in the synovial fluid originates
from the cells in the synovial membrane [15]. In addition,
adipose tissue, including that of the fat pad in the knee, is
an important source of inflammatory mediators, including
IL-6 [57,58], at least partly explaining the association of
OA with obesity. Although we did not collect information
regarding the body mass index (BMI) of the donors, it is
possible that the OA donors were more obese, which
could account at least partly for the higher levels of IL-6
found in OA synovial fluid. Furthermore, chondrocytes
can produce IL-6, although chondrocytes embedded in
their original matrix produce very little IL-6 [26]. How-
ever, during regeneration, chondrocytes produced high
levels of IL-6, which, if they were then implanted intra-
articularly, in theory, could cause high local concentrations
and affect cartilage regeneration. The production of IL-6
was not a result of the type II collagen used in this model,
as filters coated with type I collagen, which is not capable
of inducing IL-6 [32], resulted in the same IL-6 produc-
tion. Possibly, IL-6 production was induced by the TGF-b
included in the current in vitro regeneration model, as was
Figure 4 Cartilage regeneration with addition of IL-6. Cartilage regeneration cultures of three healthy (H) and three osteoarthritic (OA)
donors with addition of rhIL-6 (10 ng/mL) and rhIL-6Ra (25 ng/mL). (a-c) GAG content, GAG release and DNA content of IL-6 supplemented
samples depicted as percentage of control samples (mean ± SD); a = P = 0.009, b = P < 0.001. (d) Safranin-O staining of neocartilage generated
by chondrocytes from healthy and osteoarthritic donors without or with addition of rhIL-6. Scale bars indicate 50 μm.
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reported previously [29]. However, those data were
obtained using non-expanded chondrocytes in the short
term, rather than during regeneration culture. In addition,
the differences in IL-6 production between various cell
types cannot be explained by the addition of TGF-b, as
this was the same for all cell types.
Little is known about the role of IL-6 during regenera-
tion, but inhibition of IL-6 did not influence GAG or
DNA content of the newly formed cartilage. Possibly the
effect of IL-6 inhibition on cartilage formation was
partly masked by the regenerative effect of TGF-b. How-
ever, addition of IL-6 did decrease GAG release by OA
chondrocytes. In addition, in explant culture, no TGF-b
was present and no clear effect was found here.
The results found here are partly in contrast to the pre-
viously described reduction of cartilage matrix gene
expression and inhibition of proteoglycan synthesis
[37-39,59]. Although the latter two effects of IL-6 can be
seen as inhibitory, inhibition of synthesis can still be
accompanied by a lack of net change in proteoglycan
content if its deposition is increased. Indeed, we observed
less GAG release into the medium without affecting final
GAG content upon the addition of IL-6 to OA chondro-
cytes, suggesting that although total synthesis is reduced,
final regeneration is the same. Unfortunately this aspect
of cartilage regeneration is usually not addressed. Other
differences between the current and previous studies
evaluating the effect of IL-6 on chondrocyte metabolism
may be based on the cells used, which were mainly
bovine, porcine or rabbit chondrocytes. When human
OA chondrocytes were used, actually no effect of IL-6
was seen on aggrecan production [44]. In the current
study, addition of IL-6 to healthy chondrocytes, which
produce much less IL-6, resulted in increased GAGs
being deposited into the newly formed matrix. This is in
line with previous studies using healthy human chondro-
cytes, revealing anabolic mechanisms upon addition of
IL-6, such as up-regulation of TIMP-1 and bone mor-
phogenetic protein-7 (BMP-7) [36,60]. Furthermore, in
osteoarthritic explant culture, a trend towards decreased
0 
1
2
3 
4
5
6
control control + SF anti IL-6 + SF 
G
A
G
 re
le
as
e 
(m
g/
g 
ca
rti
la
ge
) 
0 
5
10 
15
20
25
30
control control + SF anti IL-6 + SF 
G
A
G
 c
on
te
nt
 (m
g/
g 
ca
rti
la
ge
) 
P = 0.06
0 
1 
2 
3 
4 
5 
0 
2 
4 
6 
8 
10 
IL-6 control 
control IL-6 
G
A
G
 c
on
te
nt
 (m
g/
g 
ca
rti
la
ge
) 
G
A
G
 re
le
as
e 
(m
g/
g 
ca
rti
la
ge
) 
a b
c d
Figure 5 OA cartilage explant culture with inhibition of synovial fluid IL-6 or addition of exogenous IL-6. (a, c) GAG content and GAG
release in OA cartilage explants from three donors cultured either in medium only, medium supplemented with 25% OA synovial fluid (SF) or
medium with 25% OA synovial fluid in which IL-6 is blocked with an activity-inhibiting antibody (mean ± SD in mg/g); P = 0.06. (b, d) GAG
content and GAG release in OA cartilage explants from eight donors cultured in the presence or absence of rhIL-6 (50 ng/mL) with rhIL-6Ra
(200 ng/mL).
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matrix production upon inhibition of IL-6 was observed.
Exogenous IL-6 in combination with soluble IL-6 recep-
tor in the absence of synovial fluid did not alter cartilage
turnover, suggesting that IL-6 in the synovial fluid exerts
its effects via interaction with other factors. The limited
availability of synovial fluid restricted its presence in cul-
ture to 25% and, therefore, higher percentages may have
yielded more pronounced effects. The limited effect of
IL-6 inhibition on cartilage matrix turnover is unlikely to
be due to a lack of inhibitory activity of the antibody, as
this and other similar antibodies have demonstrated
effectiveness in inhibiting IL-6 bioactivity in other mod-
els, including models with chondrocytes as target cells
[39,61]. Diffusion limitations in the cartilage explants
may have prevented complete penetration of the antibo-
dies to inhibit locally produced IL-6, thus still allowing
for paracrine signalling. However, this is probably limited
as chondrocytes in their native extracellular matrix
hardly produce IL-6 [26]. Penetration of tocilizumab,
required for the inhibition of IL-6 signalling, into the
newly formed cartilage during regeneration may have
been suboptimal, allowing IL-6 signalling through the
membrane-bound IL-6 receptor. This could explain the
lack of effect that tocilizumab had during osteoarthritic
chondrocyte regeneration.
The role of IL-6 in cartilage metabolism has been the
subject of much debate. IL-6 is often described as a mod-
ulatory factor, because it can induce both anabolic and
catabolic mechanisms. Recently, IL-6 injection into the
knee joint of mice was described to cause cartilage
destruction, but in that study, like in many others, supra
physiological concentrations of IL-6 were used [43]. Con-
centrations of IL-6 similar to those found in the synovial
fluid usually do not have effects on the expression of car-
tilage matrix proteins in cartilage [44-46]. To our knowl-
edge, this is the first study to demonstrate an effect of
physiological concentrations of IL-6 on cartilage matrix
production during regeneration, albeit modestly. IL-6 is
known to be induced by various catabolic stimuli present
in OA, such as IL-1b [30], prostaglandin E2 (PGE2) [31],
increased shear stress [62] and extracellular matrix com-
ponents such as hyaluronan fragments [63] and matril-
lin-3 [32]. IL-6, in turn, is capable of inducing factors,
such as metalloproteinases (MMPs) [64], TGFb [65], vas-
cular endothelial growth factor (VEGF) [66] and many
others which are important for tissue remodelling. In
bone IL-6 also induces remodelling through increased
osteoclastogenesis [67], which is thought to be important
in the observed inhibition of radiographic disease pro-
gression in RA patients treated with tocilizumab [6,68].
IL-6 has also been shown to have anabolic effects on car-
tilage, both indirectly through the up-regulation of fac-
tors, such as TIMP-1 [60], BMP-7 [36] and TGFb [65], as
well as directly through the up-regulation of cartilage
matrix proteins [36]. In another study, injection of IL-6
into the joint cavity of mice stimulated proteoglycan
synthesis in cartilage [69], while IL-6 knockout mice
showed more extensive naturally occurring cartilage loss
[42] and reduced proteoglycan synthesis [42,70]. The cur-
rent study indicates that IL-6 has a mainly anabolic role
in in vitro cartilage regeneration, although the effects are
not strong, with increased GAG production in healthy
chondrocytes and decreased GAG release in OA chon-
drocytes. Possibly the IL-6 in the synovial fluid of
patients with symptomatic cartilage defects is induced in
the course of regeneration and plays a role in tissue
regeneration after cartilage damage.
Although cartilage pathology seemed to clearly affect IL-
6 production and at least part of the response to interfer-
ence with this factor, several other donor-related factors
may have additionally influenced the results. To start with,
there is the typical age difference found between OA
donors (average 70 years [71]) and patients with cartilage
defects, which usually present around 30 years of age [72].
However, IL-6 levels were not found to correlate with age
[73]. The use of post-mortem collection of healthy syno-
vial fluid and cells as opposed to the intra-operative collec-
tion of OA and cartilage defect synovial fluid and cells is
less likely to have affected the results. Previous work from
our group showed that there was no difference in viability
between freshly isolated chondrocytes from healthy (post-
mortem obtained) and grade III cartilage defect tissue
[49], which is in line with the observation that viability
and cartilage matrix content is very much unaltered within
the first 24 hours [74-76]. Synovial fluid is contained in a
relatively isolated compartment [77,78] and when kept at
4°C, levels of IL-6 have been shown to be stable for more
than six hours [79].
Conclusions
This study indicates that the level of IL-6 is increased in
joints with symptomatic cartilage defects or OA compared
to healthy joints. Moreover, the elevated levels of IL-6
appear to promote anabolic metabolism of the resident
chondrocytes, and seem beneficial for formation of neo-
cartilage during in vitro regeneration. Further research is
necessary to evaluate whether targeting multiple cytokines
or pathways, including IL-6, may be an effective means to
improve cartilage matrix production during ACI or micro-
fracturing in symptomatic cartilage defects or OA.
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